Download Antiepileptic Drugs - Combination Therapy and Interactions - J. Majkowski, et al., (Cambridge, 2005) WW PDF

TitleAntiepileptic Drugs - Combination Therapy and Interactions - J. Majkowski, et al., (Cambridge, 2005) WW
File Size4.9 MB
Total Pages516
Document Text Contents
Page 1

Page 2

This page intentionally left blank

Page 258

238 John R. Pollard and Jacqueline French

trial: half dose X � half dose Y; or convert to drug Y titrated up from half dose.

This type of trial was attempted by Deckers et al. (2001) but no attempt was made

to discover if half dose of drug Y was as effective as the combination.

Bourgeois lists other designs as most likely valid such as: failure of drug X,

improvement after addition of drug Y, and then worsening after elimination of

drug X; or adding drug D to drugs X, Y, or Z and obtaining significantly better

results with one of the combinations.

In summary, the total database of proven PD interactions is far from complete.

To date, the best data for a potentially supra-additive effect on efficacy are for the

combination of lamotrigine and VPA. Studies undertaken in the future should

ideally address many of the difficulties identified above. These include: using uni-

versally accepted measures of efficacy, inefficacy, and side effects; accounting for

dropouts; using the concept of drug load; and performing well-controlled studies

that rule out pharmacokinetic interactions. For many reasons, whether cost or

ethics or unavailability of patients, we are unlikely to gain the insights into PD

interactions that the perfect studies would afford.


Bourgeois, BFD. Antiepileptic drug combinations: when two are better than one. Epilepsy

Network News 2002; 9(1): 1–3, 6.

Brodie MJ, Yuen AWC, 105 Study Group. Lamotrigine substitution study: evidence for synergism

with sodium valproate. Epilepsy Res 1997; 26: 423–432.

Cereghino JJ, Brock JT, Van Meter JC, et al. The efficacy of carbamazepine combinations in

epilepsy. Clin Pharmacol Ther 1975; 18: 733–741.

Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clini-

cal trials. Epilepsia 1999; 40(5): 590–600.

Dean JC, Penry JK. Carbamazepine/valproate therapy in 100 patients with partial seizures failing

carbamazepine monotherapy: long term follow up. Epilepsia 1988; 29: 687.

Deckers CL, Hekster YA, Keyser A, et al. Reappraisal of polytherapy in epilepsy: a critical review

of drug load and adverse effects. Epilepsia. 1997a; 38(5): 570–575.

Deckers CL, Hekster YA, Keyser A, et al. Drug load in clinical trials: a neglected factor. Clin Pharm

Ther 1997b; 62: 592–595.

Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on

mechanisms of action: The evidence reviewed. Epilepsia 2000; 41(11): 1364–1374.

Deckers CLP, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multi-

center double-blind randomized study. Epilepsia 2001; 42(11): 1387–1394.

Deckers CLP, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug therapy;

a conference review. Epilepsy Res 2003; 53: 1–17.

Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review.

Neurology 1987; 37(3): 379–385.

Page 259

239 Clinical studies of pharmacodynamic interactions

Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambula-

tory patients. Neurology 2002; 58(9): 1348–1353.

Goldsmith P, de Bittencourt PRM. Rationalized polytherapy for epilepsy. Acta Neurol Scand

Suppl 1995; 162: 35–39.

Gruber Cm, Mosier JM, Grant P, et al. Objective comparison of phenobarbital and diphenylhy-

dantoin in epileptic patients. Neurology 1956; 6: 640–645.

Hakkaraninen H. Carbamazepine vs. diphenylhydantoin vs their combination in adult epilepsy.

Neurology 1980; 30: 354.

Harden CL, Zisfein J, Atos-Radzion EC, et al. Combination valproate-carbamazepine therapy in

partial epilepsies resistant to carbamazepine monotherapy. J Epilepsy 1993; 6(2): 91–94.

Kanner AM, Frey M. Adding valproate to lamotrigine: a study of the pharmacokinetic inter-

action. Neurology 2000; 55: 588–591.

Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000; 9(7):


Lammers MW, Hekster YA, Keyser A, et al. Monotherapy of polytherapy for epilepsy revisited: a

quantitative assessment. Epilepsia 1995; 36(5): 440–446.

Mireles R, Leppik IE. Valproate and clonazepam comedication in patients with intractable

epilepsy. Epilepsia 1985; 26(2): 122–126.

Murri L, Iudice A. Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy

patients. Acta Neurol Scand Suppl 1995; 162: 40–42.

Painter MJ, Scher MS, Stein AD, Aet al. Phenobarbital compared with phenytoin for the treat-

ment of neonatal seizures. New Engl J Med 1999; 341(7): 485–489.

Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy.

Epilepsia 2002; 43(4): 365–385.

Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory

complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40(8):


Pledger GW. Drug interactions in clinical trials: statistical considerations. In Antiepileptic Drug

Interactions, Pitlick, WH. ed. New York: Demos, 1989.

Reife RA. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of

antiepileptic drugs. In Antiepileptic Drug Development. Advances in Neurology, Vol. 76. J. French,

M. A. Dichter, eds. Philadelphia: Lippincott-Raven, 1998.

Rosenberry KR, Korberly BH, Graziani LJ. Combination of clonazepam and sodium valproate in the

treatment of refractory epileptic seizures in 12 children. Am J Hosp Pharm 1979; 36(6): 736, 738.

Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate-ethosuximide combination therapy

for refractory absence seizures. Arch Neurol 1983; 40: 797–802.

Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures.

J Neurol Neurosur Psychiat 1982; 45: 1119–1124.

Sisodiya SM, Sander JWAS, Patsolos PN. Carbamazepine toxicity during combination therapy

with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 2002; 48: 217–219.

Somerville ER. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clin-

ical trials? Neurology 2002; 59(1): 79–83.

Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet

1998; 351: 958–959.

Page 515

tricyclic antidepressants (TCAs) 10, 243

interactions with anticonvulsants 357

trilazad, interactions with AEDs

phenytoin (PHT) 161

tuberculosis 4–5, 8

uridine diphosphate (UDP)-glucuronosyl-

tranferases (UDPGTs) 65–6

uridine glucuronyl transferases (UGTs) 28, 51

valproic acid and valproate (VPA) 18

action 210
active metabolites 22

adverse effects 21

effect upon excitatory amino acid receptors

effect upon NMDA and AMPA/KA

receptors 218
effects on drug-metabolizing enzyme

systems 81
elimination pathways 78
FEC and FEC index 201
fetal valproate syndrome 310

handicapped and mentally retarded

patients 330–1

influence of excitatory amino acid receptor

antagonists 215
influence of food and drugs on

bioavailability 101

interactions in children 260

interactions in the elderly

analgesics 282

anticoagulants/antiplatelet agents 280–1

CNS agents 287

gastrointestinal agents 283

interactions with newer AEDs 213
interactions with non-AEDs 163

cholestyramine 164

cimetidine 164

cisplatin 164

doxorubicin 164

ibuprofen 164–5

isoniazid 165

ketoconazole 165

mefenamic acid 165

methotrexate 165

naproxen 165

rifampicin 165

salicylic acid 165

tolbutamide 166

tolmetin 166

warfarin 166

zidovudine 166

interactions with other AEDs

effect on other drugs 118

levels through pregnancy 297
non-epileptic disorders 382

pharmacokinetic characteristics 50
pharmacokinetic interactions 21

therapeutic range 393
use of opioids in overdose 251

vecuronium, interactions with AEDs

phenytoin (PHT) 161

venlafaxine 350

verapamil, interactions with AEDs

carbamazepine (CBZ) 143

oxcarbazepine (OCBZ) 150

phenobarbital (PB) 153

vigabatrin (VGB) 18

action 30, 210
clinical trials 232

combination therapies 429

effect upon excitatory amino acid receptors

effects on drug-metabolizing enzyme

systems 81
elimination pathways 78
handicapped and mentally retarded

patients 332

influence of food and drugs on

bioavailability 102–3

interactions with non-AEDs 166

interactions with other AEDs

effect of other drugs 127

effect on other drugs 126–7

pharmacokinetic characteristics 50
selection for combination therapy 22

viloxazine 244
vincristine, interactions with AEDs

carbamazepine (CBZ) 145

warfarin, interactions with AEDs

levetiracetam (LEV) 149

oxcarbazepine (OCBZ) 150

495 Index

Page 516

warfarin, interactions with AEDs (contd)

phenobarbital (PB) 153

phenytoin (PHT) 161

tiagabine (TGB) 163

valproic acid (VPA) 166

zidovudine, interactions with AEDs

valproic acid (VPA) 166

ziprasidone 359

zolpidem 33

zonisamide (ZNS)

effects on drug-metabolizing enzyme

systems 81

elimination pathways 78
handicapped and mentally retarded

patients 334

influence of food and drugs on

bioavailability 105

interactions with non-AEDs 167

sulfonamides 167

interactions with other AEDs

effect of other drugs 130

effect on other drugs 128

pharmacokinetic characteristics 50
pharmacokinetic interactions 21

pregnancy, use in 307

496 Index

Similer Documents